ARROWHEAD RESEARCH (HDP1 MU) stock market data APIs
€58.3728
0(0%)
as of September 28, 2026
Try our APIs with
free plan!
ARROWHEAD RESEARCH Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for HDP1.MU.
Prev. Close
58.3728
Open
58.3728
High
58.3728
Low
58.3728
52 wk Range
29.1-77.66
Market Cap
6 485 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ARROWHEAD RESEARCH data using free add-ons & libraries
Get ARROWHEAD RESEARCH Fundamental Data
ARROWHEAD RESEARCH Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ARROWHEAD RESEARCH News
New
These ‘Moonshot’ Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right.
Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts. Continue Reading
Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds
Arrowhead Pharmaceuticals (ARWR) has drawn fresh attention after reporting interim Phase 1/2a data for ARO-DIMER-PA, its dual RNA interference candidate targeting atherosclerotic cardiovascular diseas...
RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics
Company Logo RNAi Therapeutics Expand on Precision Medicine Demand, Advanced Subcutaneous Delivery and Growing Rare Disease Applications Dublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "RNA Interference ...
Arrowhead Achieves Clinical Validation for New Drug Platform
Arrowhead Pharmaceuticals(NASDAQ:ARWR) on Tuesday shared interim topline clinical data from a Phase 1/2a trial. The trial is evaluating ARO-DIMER-PA, the company's first investigational RNA interfere...
Get ARROWHEAD RESEARCH fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.